Idiopathic CD4+ Lymphocytopenia Market is Driven by Advancements in Treatment Options
Idiopathic CD4+ lymphocytopenia (ICL) represents a rare immunodeficiency characterized by persistently low CD4+ T-cell counts without HIV infection. The ICL market encompasses diagnostic assays—such as flow cytometry kits and advanced immunophenotyping platforms—and therapeutic solutions including immunoglobulin replacement therapies, cytokine modulators, and emerging cell-based...
0 Σχόλια 0 Μοιράστηκε 146 Views 0 Προεπισκόπηση